Design of the Trial to Assess Chelation Therapy (TACT).

Journal Article (Journal Article)

TACT is an National Institutes of Health-sponsored, randomized, double-blind, placebo-controlled, 2 × 2 factorial clinical trial testing the benefits and risks of 40 infusions of a multicomponent disodium EDTA chelation solution compared with placebo and of an oral, high-dose multivitamin and mineral supplement. TACT has randomized and will follow up 1,708 patients for an average of approximately 4 years. The primary end point is a composite of all-cause mortality, myocardial infarction, stroke, coronary revascularization, and hospitalization for angina. A 900-patient substudy will examine quality-of-life outcomes. The trial is designed to have >85% power to detect a 25% relative reduction in the primary end point for each treatment factor. Enrollment began in September 2003 and was completed in October 2010.

Full Text

Duke Authors

Cited Authors

  • Lamas, GA; Goertz, C; Boineau, R; Mark, DB; Rozema, T; Nahin, RL; Drisko, JA; Lee, KL

Published Date

  • January 2012

Published In

Volume / Issue

  • 163 / 1

Start / End Page

  • 7 - 12

PubMed ID

  • 22172430

Pubmed Central ID

  • PMC3243954

Electronic International Standard Serial Number (EISSN)

  • 1097-6744

Digital Object Identifier (DOI)

  • 10.1016/j.ahj.2011.10.002


  • eng

Conference Location

  • United States